Cathie Wood-led Ark Invest made notable trades, buying IRDM, BEAM, PACB, ABSI and selling ILMN, RPTX, AMGN, VEEV.

PacBio shares appear undervalued ... to read my prior PacBio articles for discussions on those). Likewise, while Illumina has made noise about becoming more competitive in the long-read market ...

According to a GlobalData market model, the top three NGS companies by global market share in 2024 were Illumina, Pacific Biosciences, and Thermo Fisher Scientific. Illumina holds a 34.5% market share ...

Shares of gene-sequencing leader Illumina have fallen 17% to $101.50 since the announcement. Its smaller rivals 10X Genomics and Pacific BioSciences of California have lost 23% and 15% ...

Illumina will seek to cut $100 million in expenses by the end of this fiscal year as it plans to deal with a loss of revenue ...

Genomics company Pacific Biosciences of California (NASDAQ:PACB) will be announcing earnings results tomorrow after market hours. Here’s what investors should know. PacBio missed analysts’ revenue ...

"It's exciting to see, through our customers' results, how Callisto Apps are helping clinical labs with consistent and cost-efficient whole genome sequencing with Illumina and PacBio. Callisto is ...

University of Washington & UDN Research: Demonstrated PacBio’s ability to simultaneously analyze the genome, methylome, epigenome, and transcriptome, providing novel insights into a rare and ...

According to a GlobalData market model, the top three NGS companies by global market share in 2024 were Illumina, Pacific Biosciences, and Thermo Fisher Scientific. Illumina holds a 34.5% market ...